Aim: In order to evaluate the efficacy and safety of high versus medium doses of glucocorticoid therapy in remission induction of immunoglobulin G4-related disease (IgG4-RD), we set up a randomized controlled study.
INTRODUCTION
Immunoglobulin G4-related disease (IgG4-RD) is a chronic and systemic disease with unknown causes, characterized by the infiltration of IgG4+ plasma cells together with distinct storiform fibrosis in involved lesions and significantly increased serum IgG4 levels. [1] [2] [3] Due to the short duration of understanding of the disease, there is no uniform standard or guideline for treatment of IgG4-RD. It is widely accepted that patients with IgG4-RD are generally sensitive to glucocorticoid, with organ swelling reduced or disappearing after treatment, along with the decreasing of serum IgG4 levels. Therefore, glucocorticoid is recognized as the first-line treatment for IgG4-RD, and a good response to glucocorticoid therapy has also been listed as one of the diagnostic criteria in some areas. Although prednisone at a dosage of 30-40 mg/day is a common initial treatment for IgG4-RD, 4 in the literature, reported glucocorticoid dosage for IgG4-RD is varied, and confined to those who had limited organ involvement. 5, 6 To our knowledge, there is no randomized prospective study comparing the efficacy and side effects of high doses and medium doses of glucocorticoid in treating IgG4-RD patients. This open-labeled randomized controlled study is therefore aimed at comparing the efficacy and safety of high dose and medium dose glucocorticoid in remission induction of IgG4-RD patients.
METHODS

Trial design
This open-label 24-week randomized controlled trial (RCT) was conducted between December 2012 and October 2015. A written informed consent was obtained from each patient participating in this study. The protocol was approved by Peking Union Medical College Hospital (PUMCH) ethical review board. This trial is registered at www.ClinicalTrials.gov with the registration number NCT01758393 (release date: 12/24/ 2012), and all methods were performed in accordance with the relevant guidelines and regulations. In order to better report the treatment response, after commencement of this trial, the follow-up time was extended from 3 months to 6 months.
Setting and participants
All participates were recruited from the Department of Rheumatology in PUMCH. Patients recruited in this study met the following criteria. Inclusion criteria: newly diagnosed IgG4-RD patients were included in this study, and all met the 2011 international comprehensive diagnostic criteria 7 as follows: (i) clinical examination revealed diffuse or localized enlargement or mass formation in one or more organs; (ii) serum IgG4 concentration > 135 mg/dL; (iii) > 40% of IgG+ plasma cells being IgG4+ and > 10 cells/high-powered field of biopsy sample, together with typical tissue fibrosis or sclerosis. Meeting (i) + (ii) + (iii) is definite, meeting (i) + (iii) is probable, meeting (i) + (ii) is possible. Malignant tumor and clinical similar diseases, such as Sj€ ogren's syndrome, granulomatosis with polyangiitis, sarcoidosis, eosinophilic granulomatosis with polyangiitis and so on, were excluded.
Patients were excluded if they had the following conditions: (i) critically ill, serious infection; (ii) under 18 years of age or over 75 years old; (iii) pregnant or lactating; (iv) active viral hepatitis; and (v) serious cardiac insufficiency.
Randomization and interventions
A computer-generated randomized code was used to assign IgG4-RD patients (1 : 1) to two treatment groups. Since IgG4-RD is a rare disease, to determine the sample size, we followed the principle of obtaining the optimal sample size in clinical trials in rare diseases, 8, 9 setting up at least 20 cases in each group. The random allocation and enrolling participants were performed by different persons.
Patients were randomly assigned high doses of prednisone (0.8-1.0 mg/kg/day) and medium doses of prednisone (0.5-0.6 mg/kg/day). Four weeks later, the dosage tapered gradually, at 5-10% per 2 weeks, until maintenance dose at 7.5-10 mg/day, determined on individual patients. There were no differences of the term from attaining maintenance treatment to 24 weeks in both groups. Patients were followed up at 0, 4, 12 and 24 weeks, including treatment response, IgG4-RD responder index (IgG4-RD RI), 10 laboratory tests, such as complete blood count (CBC), hepatic and renal function, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), IgG, IgG4 and so on. Imaging studies, such as computed tomography (CT) scan, ultrasound, magnetic resonance imaging (MRI), or a 
Outcomes and measurements
Primary study endpoint was the remission rate at week 12 and week 24. Complete remission (CR) was defined as all IgG4-RD related symptoms having disappeared, and the involved lesions returning to normal; Partial remission (PR) was defined as improvement or reduction in the main involved lesions. Relapse was defined as any new or exacerbated lesions which need increasing glucocorticoid dose or to add any other immunosuppressant agents. Secondary endpoints were the changes of IgG4-RD RI, serum IgG levels, serum IgG4 levels, IgG4/IgG and inflammatory parameters.
Statistical analysis
All parameters are described in the standard summary statistics, including mean, standard deviation, minimum and maximum. Comparisons of intra-group before and after treatment were performed using the paired Wilcoxon rank test, and between different groups using the independent rank sum test. Remission ratio was analyzed by v 2 test. All statistical analyses were performed by SPSS version 19.0 (SPSS Inc., Chicago, IL, USA). A P-value < 0.05 was considered statistically significant.
RESULTS
Patient characteristics and organ involvements
A total of 42 IgG4-RD patients, 27 male and 15 female (M : F 1.8 : 1.0), were enrolled in this study, 21 cases in the high dose group and 21 cases in the medium dose group. One in each group dropped out in the first month of therapy because of intolerance to glucocorticoid, and so 40 cases completed the study. Gender distribution was male/female 1.2 : 1.0 for the high dose group and 3 : 1 for the medium dose group. The average age was 51 AE 11 years (21-65) and 55 AE 13 years (25-73) years, respectively. The average duration of illness was 21 AE 29 months (1-120 months) in the high dose group and 32 AE 43 months (1-180 months) in the medium dose group. According to the 2011 comprehensive diagnostic criteria for IgG4-RD, there were 13 definite and seven possible cases in the high dose group, 14 definite and six possible cases in the medium dose group. Detailed baseline information including laboratory findings, organ involvements, and so on are shown in Tables 1 and 2 .
Primary end point (response rate)
At week 12, the total remission rate was 95% in both groups; however, at week 24, the total remission rate in the high dose group was maintained at 95%, while in the medium dose group it reduced to 80%. In the high dose group, at week 12, 10 (50%) and nine (45%), patients achieved complete remission and partial remission, respectively; at week 24, nine (45%) and 10 (50%) patients achieved complete remission and partial remission, respectively. Only one case who All data was described as mean AE standard deviation (minimum-maximum value). RD, related disease; RI, response index; Hgb, hemoglobin; WBC, white blood cell; PLT, platelet; Ig, immunoglobulin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyltransferase; Tbil, total bilirubin; Dbil, direct bilirubin; Cr, creatinine.
achieved remission during the first month relapsed in the third month, and whose baseline IgG4-RI was 22.
He was then given cyclophosphamide in combination with corticosteroid, and improved gradually. In the medium dose group, at week 12, 12 (60%) and seven (35%) patients achieved complete remission and partial remission, respectively; at week 24, eight (40%) patients achieved complete remission and eight (40%) partial remission. There were four patients who achieved remission in the previous 3 months, but relapsed during 3-6 months, whose baseline IgG4-RI was 16, 14, 13 and 19, respectively, and immunosuppressive agents such as cyclophosphamide, methotrexate or mycophenolate were applied. As shown in Table 3 , there were no significant differences in the complete remission rate (CRR) and partial remission rate (PRR) between the two groups (CRR P = 0.752, PRR P = 0.530).
Secondary end points: changes of IgG4-RD responder index
At week 24, the IgG4-RD RI decreased from 14.9 AE 4.4 (7-22) to 3 AE 2 (0-7), (P < 0.001) in the high dose group and from 13.1 AE 4.6 (4-21) to 3.2 AE 2.8 (0-9), (P < 0.001) in the medium dose group. There was no significant difference between the two groups (P = 0.197). Detailed data are shown in Figure 1a ,b.
Changes in ESR, CRP and IgG
As shown in Table 4 , at week 24, ESR (mm/h) decreased from 47 AE 30 to 8.7 AE 9.0 (P < 0.001) in the high dose group, and from 35 AE 25 to 7.8 AE 9.3 (P < 0.001) in the medium dose group. There was no significant difference between the two groups (P = 0.409).
CRP (mg/L) decreased from 20.71 AE 30.69 to 1.57 AE 1.23 (P = 0.008) in the high dose group and from 7.14 AE 13.29 to 1.39 AE 1.91 (P = 0.039) in the medium dose group. No significant difference was shown between the two groups (P = 0.136). Meanwhile, serum IgG (g/L) decreased from 24.81 AE 7.74 to 11.62 AE 2.91 (P < 0.001) and from 21.66 AE 9.07 to 12.17 AE 3.98 (P < 0.001) in the high and medium dose groups, respectively; there was no significant difference between the two groups (P = 0.726) as well.
Serum IgG4 and IgG4/IgG ratio
The serum IgG4 (mg/dL) decreased from 1576.6 AE 1344.6 at baseline to 323.9 AE 314.4 at week 24 (P < 0.001) in the high dose group and it decreased from 1445.3 AE 1408.3 to 684.1 AE 1335.0 (P < 0.001) in the medium dose group. In the medium dose group, one patient contracted an upper respiratory infection at week 24 and his IgG4 level increased from 2360 to 5940 mg/dL but without disease relapsing. No statistically significant difference was found between the two groups (P = 0.534). The data are illustrated in Figures 1c,d and 2 .
In addition, in the high dose group, the ratio of IgG4 to IgG changed from 39.8% AE 21.3% at baseline to 27.6% AE 20.7% (P = 0.002); meanwhile, in the medium dose group, the ratio changed from 40.8% AE 18.8% to 23.7% AE 19.7% (P = 0.013). There was no significant difference between the two groups (P = 0.716), as shown in Figure 3 .
Adverse reactions
Adverse events occurred in five cases in the high dose group, in which three patients presented with extremity cramps, and two had elevated blood glucose, one of whom required insulin therapy. Two cases from the medium dose group had adverse reactions, one getting acid regurgitation and respiratory infection, the other with upper respiratory infection. No case showed severe adverse reactions and no patient discontinued treatment.
DISCUSSION
Although glucocorticoids have been shown to be effective for patients with IgG4-RD, the optimal starting dosage has not yet been standardized. No prospective randomized controlled study has been done regarding glucocorticoid induction remission treatment regimens in these patients. To our knowledge, this is the first prospective RCT comparing the efficacy of different dosages of glucocorticoid in remission induction of IgG4-RD. In this study, similar efficacy between high and medium doses of glucocorticoid was demonstrated at week 12, including complete remission rate, overall response rate, changes of IgG4-RD response index, reduction of serum IgG and IgG4 concentrations. However, at week 24, the medium dose group had a greater relapse rate than the high dose group, although there was no statistical difference between the two groups. IgG4-RD is an immune-mediated systemic fibroinflammatory condition that mimics many malignant, infectious and inflammatory disorders.
11-13
The nomenclature has been standardized, and a consensus has been achieved about the major and minor pathological manifestations. 13, 14 IgG4-RD is characterized by hyper-IgG4-gammaglobulinemia and massive IgG4+ plasma cell infiltration with typical fibrosis which cause enlargement, nodules or thickening of involved organs, either simultaneously or metachronously. In this study, all 40 patients presented hyperIgG4-gammaglobulinemia and clinical features with systemic, multi-organ involvements, including pancreas (19/40), bile duct (14/40), submandibular gland (21/ 40), lacrimal gland (17/40), parotid gland (13/40), retroperitoneal fibrosis (10/40), aorta (6/40), kidney (11/40), nasal sinus (7/40), lung (6/40), skin (5/40), prostate (4/40), lymph node (28/40) and so on. Twenty-four patients with IgG4-RD were biopsy proven.
There is no standard treatment for this disease. In the literature, the majority of studies related to IgG4-RD treatment had limitations, such as small sample size, retrospective study, or only focused on a certain organ lesion. Most clinical manifestations of IgG4-RD respond well to glucocorticoids. 15, 16 Some studies advocate combined use of glucocorticoid and immunosuppressive agents such as azathioprine, methotrexate, mycophenolate and so on. 17, 18 In addition, B cell depletion therapy with anti-CD20 antibodies (rituximab) achieved good results in both initial and refractory IgG4-RD patients. 19, 20 Glucocorticoid is generally recognized as the first choice for treatment of IgG4-RD. However, the reported dosage is varied, and no randomized treatment trial has been done. The initial dose of prednisone 0.5-0.6 mg/ kg/day in induction of remission was recommended in Japan, 16, 21 while others recommended a starting dose of 0.6-1.0 mg/kg daily. 15, 22 Recently released international consensus guidance on the treatment of IgG4-RD suggests that prednisone 30-40 mg/day is a common initial treatment. 23 The dosage can lead to clinical remission for most patients, but individually may be adjusted according to patient body weight and severity of the disease.
Very recently, Masaki et al. completed a phase II prospective clinical trial, in which 44 patients with definite IgG4-RD received prednisolone 0.6 mg/kg/day with the dose reduced every 2 weeks, and at 1 year 29 (65.9%) achieved complete remission, and the overall response rate was 93.2%. No patient was refractory to primary treatment. The most frequent adverse events were glucose intolerance. Six patients relapsed. 24 Our results are similar; the effect of glucocorticoid has been fully demonstrated, various parameters, including IgG4-RD RI score, serological indicators and clinical manifestations had significantly improved after treatment. The overall response rates at weeks 12 and 24 in the high dose group were 95% and 95%, respectively, while in the medium dose group were 95% and 80%, respectively.
Although the initial steroid treatment leads to high response in IgG4-RD patients, the high relapse rate during the maintenance period is often a big challenge. Yamamoto et al. analyzed risk factors for the relapse for patients with IgG4-RD and reported that low steroid dose at initial treatment tended to be associated with recurrence. 25 They also suggested that complication with autoimmune pancreatitis and the use of low-dose glucocorticoid at initial induction therapy tended to be associated with relapse in cases with organ involvement. In our study, although the remission rate was similar in high and medium dose groups in the previous 3 months, a higher relapse rate was observed at week 24 in the medium dose group. In agreement with Yamamoto's opinion, by further analyzing the relapsed cases, we found that their baseline IgG4-RD RIs (22, 16, 14, 13 and 19, respectively) were relatively higher among all cases (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) , which inferred that patients with more organs involved, higher IgG4-RD RI score were more likely to relapse after glucocorticoid induced remission and may require high dose steroid or additional immunosuppressive agents.
Besides good clinical response of glucocorticoid for IgG4-RD patients, serum levels of ESR, CRP, IgG and IgG4 all significantly declined. The average serum IgG concentrations in high dose and medium dose groups decreased from 24.81 d/L to 11.62 g/L, 21.66 g/L to 12.17 d/L, respectively. The average serum IgG4 concentrations decreased from 1576.6 mg/dL to 323.9 mg/ dL in the high dose group, and from 1445.3 to 684.1 mg/dL in the medium dose group. However, there was no significant difference in changes of serum IgG4 levels between the two groups. Monitoring of serum IgG4 concentrations is useful in assessment of disease activity in some patients, but it should never be used as the sole determinant in treatment decisions. The serum IgG4 concentration declines substantially after glucocorticoid treatment in most patients, but in one study did not return to the normal range in 115 (63%) of 182 patients. 15 Clinical relapses occurred in 10% of patients who had persistently normal IgG4 concentrations. 15 There are some limitations in this study. First, it is a single center study and the sample size is relatively small. Second, this study only focused on remission induction of IgG4-RD, only investigated the optimal starting dose of glucocorticoid for patients at week 24, the follow-up time was short, long-term results and optimal maintenance dose were unavailable. Third, not all patients underwent biopsy; the biopsy-proven diagnosing rate was 60%. However, in our study, all IgG4-RD patients without biopsy had elevated serum IgG4 and presented typical clinical characteristics and imaging features of IgG4-RD, and were all excluded from malignancies, infections and other IgG4-RD mimics. Although the biopsy rate is relatively low, it is similar to other cohorts; for example, in an Italy cohort, 15/41 cases (36.6%) were diagnosed as possible IgG4-RD. 26 In conclusion, glucocorticoid is an effective drug in remission induction of IgG4-RD. Our results showed that there were no statistically significant differences in the efficacy and safety between high and medium doses of glucocorticoid in the remission treatment of IgG4-RD patients. Considering the adverse effect of long-term application of glucocorticoid, we suggest that the medium dose will be the first choice for most patients in inducing remission. High dose glucocorticoid may be of benefit for patients with more organs involved and higher IgG4-RD RI score. A large multi-center clinical trial for further assessment is needed.
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